Metformin "sandoz"

Metformin, the active ingredient in Metformin sandoz, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, improving glycemic control when used alongside diet and exercise.

GNH USA supplies Metformin sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and unit‑dose requirements across multiple regulatory markets.

Metformin is indicated for the management of disorders related to impaired glucose regulation, primarily within the type 2 diabetes mellitus pathway.

Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes by modestly lowering fasting glucose levels. Gestational diabetes (when benefits outweigh risks): may be used under specialist supervision to achieve glycemic targets during pregnancy.

Metformin is generally well tolerated, but a range of adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhea: frequent loose stools, especially during dose titration. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: usually when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas reported in isolated cases.

Metformin should be used with careful clinical monitoring and patient education. - Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: caution in patients with liver disease due to lactic acidosis risk. - Lactic acidosis risk: discontinue before radiologic procedures using iodinated contrast. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk. - Contraindications: avoid in patients with known hypersensitivity to metformin. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (especially thiazides): can impair renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - NSAIDs: may reduce renal perfusion, increasing metformin exposure. - Digoxin: potential for altered plasma levels when combined with metformin.